Drug Type Monoclonal antibody |
Synonyms OS2966T |
Target |
Mechanism CD29 inhibitors(integrin subunit beta 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Phase 2 | - | 25 Apr 2022 | |
Glioblastoma Multiforme | Phase 1 | US | 02 Mar 2021 | |
High grade glioma | Phase 1 | US | 02 Mar 2021 | |
Malignant glioma of brain | Phase 1 | US | 02 Mar 2021 | |
Recurrent Malignant Glioma | Phase 1 | US | 02 Mar 2021 | |
Acute Lymphoblastic Leukemia | IND Application | - | 25 Apr 2022 | |
Acute Myeloid Leukemia | IND Application | - | 25 Apr 2022 | |
Brain Injuries, Traumatic | IND Application | - | 25 Apr 2022 | |
Psoriasis | IND Application | - | 25 Apr 2022 | |
Breast Cancer | Preclinical | US | 16 May 2024 |